N
KRYS icon

Natixis’s Krystal Biotech KRYS Stock Holding History

Natixis’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$448K Sell
1,736
-1,184
-41% -$315K ﹤0.01% 826
2025
Q4 		$720K Buy
2,920
+2,798
+2,293% +$589K ﹤0.01% 779
2025
Q3 		$21.5K Buy
+122
New +$18.3K ﹤0.01% 964
2023
Q1 		– Sell
-4,000
Closed -$317K – 1099
2022
Q4 		$317K Buy
+4,000
New +$297K ﹤0.01% 770

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Natixis's KRYS Position: Q1 2026 in Review

Natixis reduced its Krystal Biotech (KRYS) stake by 41% in Q1 2026, selling an estimated $315K and leaving 1,736 shares worth $448K. The position accounts for ﹤0.01% of the portfolio, ranked #826.

Natixis first reported a position in KRYS in Q4 2022 and has held it in 4 quarters since. The position peaked at $720K in Q4 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Natixis held 1,736 shares of Krystal Biotech worth $448K as of Q1 2026.
  • Natixis sold 1,184 Krystal Biotech shares in Q1 2026, an estimated $315K.
  • Krystal Biotech made up ﹤0.01% of Natixis's portfolio in Q1 2026, its #826 holding.
  • Natixis first reported a position in Krystal Biotech in Q4 2022 and has held it in 4 quarters since.
  • Natixis's Krystal Biotech position peaked at $720K in Q4 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.